Schizophrenia is a devastating mental illness and its effective treatment is among the most
challenging issues in psychiatry. The symptoms of schizophrenia are heterogeneous …

Highlights•Drugs for schizophrenia are often based on dopamine blockade and have
serious side-effects.•Xanomeline/trospium may well herald the first non-dopamine based …

The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in
Alzheimer's disease and schizophrenia. We present data on the effect of KarXT (xanomeline …

Background Negative symptoms and cognitive impairments predict difficulties in aspects of
everyday functioning in schizophrenia, with little research to date attempting to determine if …

Cognitive impairment associated with schizophrenia (CIAS) is widely regarded as a critically
important treatment target for schizophrenia. Despite major efforts and a number of …

Rodent models have facilitated major discoveries in neurobiology, however, the low success
rate of novel medications in clinical trials have led to questions about their translational …

Objective: Xanomeline and trospium chloride (formerly known as KarXT), a novel M1/M4
muscarinic receptor agonist, demonstrated efficacy across phase 2 and 3 trials as …

There are currently no regulatory approved pharmacological treatments for cognitive
impairment associated with schizophrenia (CIAS). One possibility is that trial methodology …

Conclusions• KarXT was associated with a significant benefit in cognitive performance vs
placebo, both when analyses were limited to impaired patients and in those without …